Cataract 3, Multiple Types (CTRCT3) via the CRYBB2 Gene

  • Summary and Pricing
  • Clinical Features and Genetics
  • Citations
  • Methods
  • Ordering/Specimens
Order Kits


Test Code Test Copy GenesIndividual Gene PriceCPT Code Copy CPT Codes
2904 CRYBB2$610.00 81479 Add to Order
Targeted Testing

For ordering targeted known variants, please proceed to our Targeted Variants landing page.

Turnaround Time

The great majority of tests are completed within 18 days.

Clinical Sensitivity

The clinical sensitivity of this test may range up to 10%. In three independent investigations performed in China, none (0/25; Sun et al. 2011), 5.6% (1/18; Sun et al. 2014), and 10% (2/20; Wang et al. 2011) of families with congenital cataracts harbored pathogenic sequence variants in the CRYBB2 gene. In two independent studies conducted in India, 1.7% (1/60; Devi et al. 2008), 2% (2/100; Kumar et al. 2013) of families with inherited pediatric cataract tested positive for disease-causing CRYBB2 sequence variants. In Denmark, 7% (2/28) of families with hereditary congenital cataract carried a pathogenic sequence variant in the CRYBB2 gene (Hansen et al. 2009).

See More

See Less

Clinical Features

Cataract 3 (CTRCT3) is common congenital, bilateral, symmetrical, progressive, polymorphic vision disorder that causes blindness in children (Litt et al. 1997). It consists of multiple types of cataracts that have been described as structural cataracts with punctate and cerulean (peripheral bluish and white opacification in concentric layers) opacities (Pauli et al. 2007). CTRCT3 is characterized by the development of blurred and dimmed vision resulting from clouding of the lens (opacification) due to changes in its microarchitecture (Kumar et al. 2013). This particular damage to the lens induces light to scatter as well as proteins to aggregate, thereby resulting in loss of transparency (Hejtmancik 1998). Intrafamilial variability in the size and density of the sutural opacity or in the number and position of the cerulean spots commonly occurs in CTRCT3 (Vanita et al. 2001; Lou et al. 2009; Weisschuh et al. 2012). The majority of individuals with CTRCT3 notice visual impairment before the age of 10 (Kramer et al. 1996; Li et al. 2008; Mothobi et al. 2009). The incidence of congenital cataract has been estimated to be roughly 2.5 per 10,000 live births (Wirth et al. 2002; Yi et al. 2011). Perinatal ocular examination in newborns via red reflex examination is generally conducted using an ophthalmoscope (American Academy of Pediatrics 2002), whereas young children are assessed by slit-lamp microscopy (Yao et al. 2005, 2011; Li et al. 2013). Congenital cataract is usually treated by surgery and early primary intraocular lens implantation during the first year of life (Ventura et al. 2013). Some individuals with CTRCT3 may exhibit microphthalmia, microcornea, and strabismus (Kramer et al. 1996).


CTRCT3 is an autosomal dominant vision disorder that is caused by pathogenic sequence variants in the crystallin, beta-B2 (CRYBB2) gene, which is located on chromosome 22q11.23 (Kramer et al. 1996; Garnai et al. 2014). The CRYBB2 gene consists of five coding exons that encode a 205-amino acid structural protein called beta-crystallin B2, which is the most abundant and water-soluble beta-crystallin protein in the epithelial cells of the human lens (Gill et al. 2000). The CRYBB2 protein plays an important structural role in the maintenance of lens transparency and refractive index (Chen et al. 2013). Pathogenic sequence variants in the CRYBB2 gene significantly reduces the solubility and changes biophysical properties of the beta-crystallin B2, which are critical for lens transparency (Liu and Liang 2005; Chen et al. 2013). To date, a total of about 20 pathogenic CRYBB2 sequence variants have been reported, which are mostly missense and a few chain terminations (nonsense) and complex rearrangements (Human Gene Mutation Database). A recent study has indicated that the CRYBB2 protein is also expressed in the mammalian brain and may play a role in hippocampal function and behavioral phenotypes (Sun et al. 2013).

Testing Strategy

This test involves bidirectional DNA Sanger sequencing of all coding exons and ~10 bp of flanking noncoding sequence of CRYBB2. We will also sequence any single exon (Test #100) in family members of patients with a known mutation or to confirm research results.

Indications for Test

The ideal CRYBB2 test candidates are individuals who present with congenital cataracts.


Official Gene Symbol OMIM ID
CRYBB2 123620
Inheritance Abbreviation
Autosomal Dominant AD
Autosomal Recessive AR
X-Linked XL
Mitochondrial MT


Name Inheritance OMIM ID
Cataract 3 AD 601547

Related Test

Congenital Cataracts Sequencing Panel


Genetic Counselors
  • American Academy of Pediatrics. 2002. Pediatrics. 109: 980-1. PubMed ID: 11986467
  • Chen W. et al. 2013. Plos One. 8: e81290. PubMed ID: 24312286
  • Devi R.R. et al. 2008. Molecular Vision. 14: 1157-70. PubMed ID: 18587492
  • Garnai S.J. et al. 2014. Molecular Vision. 20: 1579-93. PubMed ID: 25489230
  • Gill D. et al. 2000. Investigative Ophthalmology & Visual Science. 41: 159-65. PubMed ID: 10634616
  • Hansen L. et al. 2009. Investigative Ophthalmology & Visual Science. 50: 3291-303. PubMed ID: 19182255
  • Hejtmancik J.F. 1998. American Journal of Human Genetics. 62: 520-5. PubMed ID: 9497271
  • Human Gene Mutation Database (Bio-base).
  • Kramer P. et al. 1996. Genomics. 35: 539-42. PubMed ID: 8812489
  • Kumar M. et al. 2013. Molecular Vision. 19: 2436-50. PubMed ID: 24319337
  • Li Fei-feng et al. 2008. Molecular Vision. 14: N/A. PubMed ID: 18449377
  • Li L.H. et al. 2013. The British Journal of Ophthalmology. 97: 588-91. PubMed ID: 23426739
  • Litt M. et al. 1997. Human Molecular Genetics. 6: 665-8. PubMed ID: 9158139
  • Liu B.F., Liang J.J. 2005. Molecular Vision. 11: 321-7. PubMed ID: 15889016
  • Lou D. et al. 2009. Eye (London, England). 23: 1213-20. PubMed ID: 18617901
  • Mothobi M.E. et al. 2009. Molecular Vision. 15: 1470-5. PubMed ID: 19649175
  • Pauli S. et al. 2007. Molecular Vision. 13: 962-7. PubMed ID: 17653036
  • Sun M. et al. 2013. Mammalian Genome. 24: 333-48. PubMed ID: 24096375
  • Sun W. et al. 2011. Molecular vision. 17: 2197-206. PubMed ID: 21866213
  • Sun W. et al. 2014. Plos One. 9: e100455. PubMed ID: 24968223
  • Vanita V. et al. 2001. J. Med. Genet. 38: 396-400. PubMed ID: 11424921
  • Ventura M.C. et al. 2013. Arquivos Brasileiros De Oftalmologia. 76: 240-3. PubMed ID: 24061837
  • Wang K.J. et al. 2011. Archives of Ophthalmology (Chicago, Ill.: 1960). 129: 337-43. PubMed ID: 21402992
  • Weisschuh N. et al. 2012. Molecular Vision. 18: 174-80. PubMed ID: 22312185
  • Wirth M.G. et al. 2002. The British Journal of Ophthalmology. 86: 782-6. PubMed ID: 12084750
  • Yao K. et al. 2005. Molecular Vision. 11: 758-63. PubMed ID: 16179907
  • Yao K. et al. 2011. Molecular Vision. 17: 144-52. PubMed ID: 21245961
  • Yi J. et al. 2011. International Journal of Ophthalmology. 4: 422-32. PubMed ID: 22553694
Order Kits

Bi-Directional Sanger Sequencing

Test Procedure

Nomenclature for sequence variants was from the Human Genome Variation Society (  As required, DNA is extracted from the patient specimen.  PCR is used to amplify the indicated exons plus additional flanking non-coding sequence.  After cleaning of the PCR products, cycle sequencing is carried out using the ABI Big Dye Terminator v.3.0 kit.  Products are resolved by electrophoresis on an ABI 3730xl capillary sequencer.  In most cases, sequencing is performed in both forward and reverse directions; in some cases, sequencing is performed twice in either the forward or reverse directions.  In nearly all cases, the full coding region of each exon as well as 10 bases of non-coding DNA flanking the exon are sequenced.

Analytical Validity

As of February 2018, we compared 26.8 Mb of Sanger DNA sequence generated at PreventionGenetics to NextGen sequence generated in other labs. We detected only 4 errors in our Sanger sequences, and these were all due to allele dropout during PCR. For Proficiency Testing, both external and internal, in the 14 years of our lab operation we have Sanger sequenced roughly 14,300 PCR amplicons. Only one error has been identified, and this was an error in analysis of sequence data.

Our Sanger sequencing is capable of detecting virtually all nucleotide substitutions within the PCR amplicons. Similarly, we detect essentially all heterozygous or homozygous deletions within the amplicons. Homozygous deletions which overlap one or more PCR primer annealing sites are detectable as PCR failure. Heterozygous deletions which overlap one or more PCR primer annealing sites are usually not detected (see Analytical Limitations). All heterozygous insertions within the amplicons up to about 100 nucleotides in length appear to be detectable. Larger heterozygous insertions may not be detected. All homozygous insertions within the amplicons up to about 300 nucleotides in length appear to be detectable. Larger homozygous insertions may masquerade as homozygous deletions (PCR failure).

Analytical Limitations

In exons where our sequencing did not reveal any variation between the two alleles, we cannot be certain that we were able to PCR amplify both of the patient’s alleles. Occasionally, a patient may carry an allele which does not amplify, due for example to a deletion or a large insertion. In these cases, the report contains no information about the second allele.

Similarly, our sequencing tests have almost no power to detect duplications, triplications, etc. of the gene sequences.

In most cases, only the indicated exons and roughly 10 bp of flanking non-coding sequence on each side are analyzed. Test reports contain little or no information about other portions of the gene, including many regulatory regions.

In nearly all cases, we are unable to determine the phase of sequence variants. In particular, when we find two likely causative mutations for recessive disorders, we cannot be certain that the mutations are on different alleles.

Our ability to detect minor sequence variants, due for example to somatic mosaicism is limited. Sequence variants that are present in less than 50% of the patient’s nucleated cells may not be detected.

Runs of mononucleotide repeats (eg (A)n or (T)n) with n >8 in the reference sequence are generally not analyzed because of strand slippage during PCR and cycle sequencing.

Unless otherwise indicated, the sequence data that we report are based on DNA isolated from a specific tissue (usually leukocytes). Test reports contain no information about gene sequences in other tissues.

Order Kits

Ordering Options

myPrevent - Online Ordering
  • The test can be added to your online orders in the Summary and Pricing section.
  • Once the test has been added log in to myPrevent to fill out an online requisition form.
  • A completed requisition form must accompany all specimens.
  • Billing information along with specimen and shipping instructions are within the requisition form.
  • All testing must be ordered by a qualified healthcare provider.


(Delivery accepted Monday - Saturday)

  • Collect 3 ml -5 ml (5 ml preferred) of whole blood in EDTA (purple top tube) or ACD (yellow top tube). For Test #500-DNA Banking only, collect 10 ml -20 ml of whole blood.
  • For small babies, we require a minimum of 1 ml of blood.
  • Only one blood tube is required for multiple tests.
  • Ship blood tubes at room temperature in an insulated container. Do not freeze blood.
  • During hot weather, include a frozen ice pack in the shipping container. Place a paper towel or other thin material between the ice pack and the blood tube.
  • In cold weather, include an unfrozen ice pack in the shipping container as insulation.
  • At room temperature, blood specimen is stable for up to 48 hours.
  • If refrigerated, blood specimen is stable for up to one week.
  • Label the tube with the patient name, date of birth and/or ID number.


(Delivery accepted Monday - Saturday)

  • Send in screw cap tube at least 5 µg -10 µg of purified DNA at a concentration of at least 20 µg/ml for NGS and Sanger tests and at least 5 µg of purified DNA at a concentration of at least 100 µg/ml for gene-centric aCGH, MLPA, and CMA tests, minimum 2 µg for limited specimens.
  • For requests requiring more than one test, send an additional 5 µg DNA per test ordered when possible.
  • DNA may be shipped at room temperature.
  • Label the tube with the composition of the solute, DNA concentration as well as the patient’s name, date of birth, and/or ID number.
  • We only accept genomic DNA for testing. We do NOT accept products of whole genome amplification reactions or other amplification reactions.


(Delivery preferred Monday - Thursday)

  • PreventionGenetics should be notified in advance of arrival of a cell culture.
  • Culture and send at least two T25 flasks of confluent cells.
  • Some panels may require additional flasks (dependent on size of genes, amount of Sanger sequencing required, etc.). Multiple test requests may also require additional flasks. Please contact us for details.
  • Send specimens in insulated, shatterproof container overnight.
  • Cell cultures may be shipped at room temperature or refrigerated.
  • Label the flasks with the patient name, date of birth, and/or ID number.
  • We strongly recommend maintaining a local back-up culture. We do not culture cells.
loading Loading... ×